Ikena Oncology (IMA) EBITDA (2020 - 2026)
Ikena Oncology (IMA) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM Ikena Oncology (IMA) EBITDA is -$54M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Ikena Oncology (IMA) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +126.68% |
| 3 Years TTM | -7.62% |
| 5 Years TTM | +2.98% |
| All Time TTM | +2.98% |
Annual EBITDA change of Ikena Oncology (IMA)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$12M | -74.86% |
| 2025 | -$48M | +33.84% |
| 2024 | -$36M | -51.75% |
| 2023 | -$74M | +6.06% |
| 2022 | -$70M | +108.84% |
| 2021 | -$34M | -24.04% |
| 2020 | -$44M | N/A |
Comparison Ikena Oncology (IMA) five years EBITDA CAGR with competitors
Ikena Oncology (IMA) five years EBITDA CAGR is 2.98%.